Viridian Therapeutics, Inc.
VRDN
$18.83
$0.814.50%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 75.00K | 72.00K | 72.00K | 86.00K | 72.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 75.00K | 72.00K | 72.00K | 86.00K | 72.00K |
| Cost of Revenue | 86.63M | 5.75M | 238.25M | -- | 56.19M |
| Gross Profit | -86.55M | -5.68M | -238.18M | 86.00K | -56.12M |
| SG&A Expenses | 20.22M | 17.10M | 15.58M | 14.41M | 16.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 106.84M | 93.94M | 87.54M | 83.57M | 72.26M |
| Operating Income | -106.77M | -93.87M | -87.47M | -83.48M | -72.19M |
| Income Before Tax | -100.74M | -86.91M | -79.73M | -76.69M | -64.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -100.74M | -86.91M | -79.73M | -76.69M | -64.99M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -100.74M | -86.91M | -79.73M | -76.69M | -64.99M |
| EBIT | -106.77M | -93.87M | -87.47M | -83.48M | -72.19M |
| EBITDA | -106.65M | -93.75M | -87.35M | -83.35M | -72.05M |
| EPS Basic | -1.00 | -0.87 | -0.23 | -1.15 | -0.77 |
| Normalized Basic EPS | -0.77 | -0.67 | -0.62 | -0.72 | -0.64 |
| EPS Diluted | -1.00 | -0.87 | -0.23 | -1.15 | -0.77 |
| Normalized Diluted EPS | -0.77 | -0.67 | -0.62 | -0.72 | -0.64 |
| Average Basic Shares Outstanding | 81.59M | 81.34M | 80.05M | 66.42M | 63.85M |
| Average Diluted Shares Outstanding | 81.59M | 81.34M | 80.05M | 66.42M | 63.85M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |